Current use of CAR T cells to treat multiple myeloma Review

   


Authors: Firestone, R. S.; Mailankody, S.
Review Title: Current use of CAR T cells to treat multiple myeloma
Abstract: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies currently approved by the US Food and Drug Administration (FDA) have dramatically improved clinical outcomes for patients with heavily pretreated multiple myeloma who have disease refractory to conventional proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. However, despite this progress, multiple myeloma remains an incurable hematologic malignancy. In this review, we discuss practical considerations for currently FDA approved CAR T-cell therapies, including newer data evaluating those agents in earlier lines of therapy. We also discuss considerations for patients following relapse from anti-BCMA CAR T-cell therapy, which currently represents an unmet clinical need. Copyright © 2023 by The American Society of Hematology.
Keywords: t lymphocyte; t-lymphocytes; multiple myeloma; neoplasm recurrence, local; pathology; tumor recurrence; chimeric antigen receptor; adoptive immunotherapy; immunotherapy, adoptive; humans; human; receptors, chimeric antigen
Journal Title: Hematology-American Society of Hematology Education Program
Volume: 2023
Issue: 1
ISSN: 1520-4391
Publisher: American Society of Hematology  
Date Published: 2023-12-01
Start Page: 340
End Page: 347
Language: English
DOI: 10.1182/hematology.2023000434
PUBMED: 38066841
PROVIDER: scopus
PMCID: PMC10727084
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85179645053&doi=10.1182%2fhematology.2023000434&partnerID=40&md5=44e9db6a75d26abb0396fa0e2ef9de25
Notes: Review -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Sham Mailankody
    282 Mailankody
  2. Ross Firestone
    35 Firestone
Related MSK Work